## Kyung-min Lee

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1619889/publications.pdf

Version: 2024-02-01

58 papers	2,654 citations	24 h-index	197818 49 g-index
65	65	65	6877 citing authors
all docs	docs citations	times ranked	

#	Article	IF	Citations
1	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metabolism, 2017, 26, 633-647.e7.	16.2	449
2	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nature Communications, 2019, 10, 1373.	12.8	252
3	Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity. European Journal of Neuroscience, 2004, 19, 3375-3381.	2.6	222
4	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Research, 2017, 77, 2488-2499.	0.9	178
5	Activation of p38 MAP kinase in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury. NeuroReport, 2002, 13, 2483-2486.	1.2	156
6	A versatile oblique plane microscope for large-scale and high-resolution imaging of subcellular dynamics. ELife, 2020, 9, .	6.0	120
7	Neuronal Autophagy and Neurodevelopmental Disorders. Experimental Neurobiology, 2013, 22, 133-142.	1.6	97
8	CD44 regulates cell proliferation, migration, and invasion via modulation of c-Src transcription in human breast cancer cells. Cellular Signalling, 2015, 27, 1882-1894.	3.6	88
9	ECM1 regulates tumor metastasis and CSC-like property through stabilization of $\hat{l}^2$ -catenin. Oncogene, 2015, 34, 6055-6065.	5.9	78
10	Interleukinâ€6 induces microglial CX3CR1 expression in the spinal cord after peripheral nerve injury through the activation of p38 MAPK. European Journal of Pain, 2010, 14, 682.e1-12.	2.8	70
11	Regulation of Cell Proliferation and Migration by Keratin19-Induced Nuclear Import of Early Growth Response-1 in Breast Cancer Cells. Clinical Cancer Research, 2013, 19, 4335-4346.	7.0	68
12	Tumor necrosis factor receptor 1 induces interleukinâ€6 upregulation through NFâ€kappaB in a rat neuropathic pain model. European Journal of Pain, 2009, 13, 794-806.	2.8	61
13	Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling. Breast Cancer Research, 2014, 16, 479.	5.0	58
14	Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. Breast Cancer Research, 2019, 21, 146.	5.0	52
15	Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell, 2021, 39, 1099-1114.e8.	16.8	45
16	CD24 enhances DNA damage-induced apoptosis by modulating NF-κB signaling in CD44-expressing breast cancer cells. Carcinogenesis, 2011, 32, 1474-1483.	2.8	44
17	Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. Journal of Medicinal Chemistry, 2019, 62, 3971-3988.	6.4	44
18	ECM1 promotes the Warburg effect through EGF-mediated activation of PKM2. Cellular Signalling, 2015, 27, 228-235.	3.6	40

#	Article	IF	CITATIONS
19	Protein kinase B/Akt1 inhibits autophagy by down-regulating UVRAG expression. Experimental Cell Research, 2013, 319, 122-133.	2.6	34
20	Cytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes. Cell Death and Differentiation, 2015, 22, 665-676.	11.2	34
21	Isolation of CD24high and CD24low/â <sup></sup> cells from MCF-7: CD24 expression is positively related with proliferation, adhesion and invasion in MCF-7. Cancer Letters, 2007, 258, 98-108.	7.2	33
22	Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. Cancer Cell, 2020, 37, 183-199.e5.	16.8	33
23	Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer. Clinical Cancer Research, 2021, 27, 4379-4396.	7.0	30
24	<i>PIK3CA</i> C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K <b<math>\hat{l}± Inhibitors. Clinical Cancer Research, 2018, 24, 1426-1435.</b<math>	7.0	27
25	ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. Clinical Cancer Research, 2018, 24, 2517-2529.	7.0	26
26	Activation of transcription factor c-jun in dorsal root ganglia induces VIP and NPY upregulation and contributes to the pathogenesis of neuropathic pain. Experimental Neurology, 2007, 204, 467-472.	4.1	25
27	Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. Nature Communications, 2020, 11, 5488.	12.8	25
28	HER2 stabilizes survivin while concomitantly down-regulating survivin gene transcription by suppressing Notch cleavage. Biochemical Journal, 2013, 451, 123-134.	3.7	24
29	Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer. Oncotarget, 2016, 7, 38500-38512.	1.8	24
30	CD24 regulates cell proliferation and transforming growth factor $\hat{l}^2 \hat{a} \in \hat{l}$ induced epithelial to mesenchymal transition through modulation of integrin $\hat{l}^2 1$ stability. Cellular Signalling, 2012, 24, 2132-2142.	3.6	22
31	Akt isoform-specific inhibition of MDA-MB-231 cell proliferation. Cellular Signalling, 2011, 23, 19-26.	3.6	20
32	CD24 regulates stemness and the epithelial to mesenchymal transition through modulation of Notch1 mRNA stability by p38MAPK. Archives of Biochemistry and Biophysics, 2014, 558, 120-126.	3.0	18
33	Induction of apoptotic cell death by Pharbitis nil extract in HER2-overexpressing MCF-7 cells. Journal of Ethnopharmacology, 2011, 133, 126-131.	4.1	15
34	Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. Cancer Immunology Research, 2022, 10, 829-843.	3.4	12
35	Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance. Biomedicines, 2022, 10, 1130.	3.2	11
36	Drug response of captured BT20 cells and evaluation of circulating tumor cells on a silicon nanowire platform. Biosensors and Bioelectronics, 2015, 67, 370-378.	10.1	10

#	Article	IF	CITATIONS
37	Nicotinamide (niacin) supplement increases lipid metabolism and ROSâ€induced energy disruption in tripleâ€negative breast cancer: potential for drug repositioning as an antiâ€tumor agent. Molecular Oncology, 2022, 16, 1795-1815.	4.6	10
38	S100A4 negatively regulates $\hat{l}^2$ -catenin by inducing the Egr-1-PTEN-Akt-GSK3 $\hat{l}^2$ degradation pathway. Cellular Signalling, 2014, 26, 2096-2106.	3.6	9
39	Abstract 3328: MYC and MCL1 cooperatively promote chemotherapy-resistant cancer stem cells through regulation of mitochondrial biogenesis and oxidative phosphorylation. Cancer Research, 2016, 76, 3328-3328.	0.9	9
40	Discovery of Proteins Responsible for Resistance to Three Chemotherapy Drugs in Breast Cancer Cells Using Proteomics and Bioinformatics Analysis. Molecules, 2022, 27, 1762.	3.8	9
41	EGFR negates the proliferative effect of oncogenic HER2 in MDA-MB-231 cells. Archives of Biochemistry and Biophysics, 2015, 575, 69-76.	3.0	7
42	Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer. Breast Cancer Research, 2020, 22, 130.	5.0	7
43	Aged wild-type littermates and APPswe+PS1/ΔE9 mice present similar deficits in associative learning and spatial memory independent of amyloid load. Genes and Genomics, 2010, 32, 63-70.	1.4	6
44	Effects of Endocrine Disruptors onBombina orientalisP450 Aromatase Activity. Zoological Science, 2010, 27, 338-343.	0.7	6
45	Association of low-dose exposure to persistent organic pollutants with <i>E-cadherin </i> promoter methylation in healthy Koreans. Biomarkers, 2018, 23, 293-298.	1.9	5
46	Protein expression profiling of primary mammary epithelial cells derived from MMTVâ€∢i>neu⟨/i> mice revealed that HER2/NEUâ€driven changes in protein expression are functionally clustered. IUBMB Life, 2010, 62, 41-50.	3.4	4
47	Quantitative Proteomics Reveals Knockdown of CD44 Promotes Proliferation and Migration in Claudin-Low MDA-MB-231 and Hs 578T Breast Cancer Cell Lines. Journal of Proteome Research, 2021, 20, 3720-3733.	3.7	4
48	Tryptophanyl-tRNA Synthetase Sensitizes Hormone Receptor-Positive Breast Cancer to Docetaxel-Based Chemotherapy. Journal of Breast Cancer, 2020, 23, 599.	1,9	3
49	ECM1 is associated with endocrine resistance in ER <sup>+</sup> breast cancers. Animal Cells and Systems, 2022, 26, 99-107.	2.2	3
50	Abstract GS6-06: A neoadjuvant trial with letrozole identifies PRR11 in the $17q23$ amplicon as a mechanism of resistance to endocrine therapy in ER-positive breast cancer., 2020,,.		2
51	Downregulation of N-myc and STAT Interactor Protein Predicts Aggressive Tumor Behavior and Poor Prognosis in Invasive Ductal Carcinoma. Journal of Breast Cancer, 2020, 23, 36.	1.9	1
52	Abstract GS3-09: Loss of <i>ASXL1</i> tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer. Cancer Research, 2022, 82, GS3-09-GS3-09.	0.9	1
53	The possibility of low isomerization of $\hat{l}^2$ -lapachone in the human body. Translational and Clinical Pharmacology, 2021, 29, 160.	0.9	0
54	The G12 family proteins upregulate matrix metalloproteinaseâ€2 and invasion in human breast epithelial cells. FASEB Journal, 2009, 23, 740.1.	0.5	0

#	Article	IF	CITATIONS
55	Abstract 3890: Mitochondrial MCL1 maintains triple negative breast cancer stem cells and contributes to chemotherapy resistance. , 2017, , .		0
56	Hyperactivation of Torc 1 Drives Resistance to the Pan-Her Tyrosine Kinase Inhibitor Neratinib in Her 2-Mutant Cancers. SSRN Electronic Journal, 0, , .	0.4	0
57	Abstract 4402: FGFR1 signaling modulates estrogen-independent ER transcriptional activity in ER+/FGFR1-amplified breast cancer cells. , 2019, , .		O
58	Abstract PD7-04: Fibroblast growth factor receptor 1 associates with promoters genome-wide and regulates gene transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance. , 2020, , .		0